Analysts have set 12-month price targets for BeiGene, revealing an average target of $330.25, a high estimate of $348.00, and ...

--Up 12.72% at today's intraday high; largest intraday percent increase since March 13, 2024, when it rose as much as 12.85% Though they varied in length and severity, the market always recovered and ...

Ebn Sina Medical, a subsidiary of Aamal Company Q.P.S.C. and a leading supplier of pharmaceutical, hospital, and healthcare ...

BeiGene (NasdaqGS:ONC) has climbed 32% over the past quarter, against a backdrop of significant industry challenges and broad market declines. The company's positive momentum can be attributed to the ...

Beigene (NASDAQ:ONC – Get Free Report) is one of 1,072 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its peers? We will compare Beigene ...

Under this agreement, Ebn Sina Medical will serve as the local partner and distributor for BeiGene’s range of oncology ...

Fintel reports that on April 7, 2025, RBC Capital initiated coverage of BeiGene, - Depositary Receipt () (NasdaqGS:ONC) with ...

DOHA: Ebn Sina Medical, a subsidiary of Aamal Company Q.P.S.C., has signed a strategic partnership with BeiGene, a global ...

RBC Capital initiated coverage of BeiGene (ONC) with an Outperform rating and $312 price target RBC sees a path to robust revenue growth ...